INT54895

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.48
First Reported 1994
Last Reported 2010
Negated 1
Speculated 1
Reported most in Body
Documents 24
Total Number 26
Disease Relevance 11.38
Pain Relevance 4.48

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (Epo) aging (Epo) extracellular region (Epo)
Anatomy Link Frequency
brain 2
pancreatic islets 1
plasma 1
retina 1
bone marrow 1
Epo (Rattus norvegicus)
Pain Link Frequency Relevance Heat
lidocaine 21 99.76 Very High Very High Very High
palliative 2 99.74 Very High Very High Very High
Inflammation 11 99.16 Very High Very High Very High
Pain 12 99.08 Very High Very High Very High
ischemia 156 98.48 Very High Very High Very High
cytokine 87 97.88 Very High Very High Very High
Analgesic 4 97.18 Very High Very High Very High
fibrosis 4 93.76 High High
Demyelination 6 90.80 High High
local anesthetic 3 90.48 High High
Disease Link Frequency Relevance Heat
Hypoxia 211 100.00 Very High Very High Very High
Hypercalcemia 2 100.00 Very High Very High Very High
INFLAMMATION 16 99.16 Very High Very High Very High
Pain 4 99.08 Very High Very High Very High
Malignant Neoplastic Disease 4 98.84 Very High Very High Very High
Brain Hemorrhage 16 98.48 Very High Very High Very High
Disease 14 98.44 Very High Very High Very High
Fibrosis 2 98.20 Very High Very High Very High
Embolism 24 97.52 Very High Very High Very High
Sepsis 82 96.64 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
OBJECTIVE: To compare the analgesic effects of non nutritive pacifier sucking, oral administration of a 30% saccharose solution, local application of Emla and their association for subcutaneous injection of erythropoietin (EPO) in preterm infants.
EPO Binding (association) of associated with analgesic
1) Confidence 0.48 Published 2004 Journal Arch Pediatr Section Abstract Doc Link 15288082 Disease Relevance 0 Pain Relevance 0.17
OBJECTIVE: To compare the analgesic effects of non nutritive pacifier sucking, oral administration of a 30% saccharose solution, local application of Emla and their association for subcutaneous injection of erythropoietin (EPO) in preterm infants.
erythropoietin Binding (association) of associated with analgesic
2) Confidence 0.48 Published 2004 Journal Arch Pediatr Section Abstract Doc Link 15288082 Disease Relevance 0 Pain Relevance 0.17
Proposed is a unifying model of cumulative risk factors in which the interplay of systemic inflammation and stimulated hematopoietic environment associated with hyperparathyroidism and erythropoietin may tie to a common pathogenic mechanism of fibrogenesis.
erythropoietin Binding (associated) of associated with fibrosis, inflammation and hypercalcemia
3) Confidence 0.47 Published 2007 Journal J. Am. Soc. Nephrol. Section Abstract Doc Link 17855637 Disease Relevance 0.94 Pain Relevance 0.35
However, additional experiments are warranted to examine whether EPO interacts with other mitogenic factors to promote OPC proliferation.
EPO Spec (whether) Binding (interacts) of
4) Confidence 0.47 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2884017 Disease Relevance 1.06 Pain Relevance 0.17
bound to the HRE of the EPO promoter and turned on the expression of EPO.
EPO Binding (bound) of
5) Confidence 0.42 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2852409 Disease Relevance 0.19 Pain Relevance 0.03
In addition proliferation markers were increased after hepatectomy until 3 days on rats treated with rhEPO, similarly to our results [8].
rhEPO Binding (treated) of
6) Confidence 0.37 Published 2010 Journal World J Surg Oncol Section Body Doc Link PMC2917416 Disease Relevance 0.10 Pain Relevance 0
Subcutaneous injections of recombinant human erythropoietin (rHuEPO) produce considerable pain which can result in noncompliance.
rHuEPO Binding (injections) of associated with pain
7) Confidence 0.37 Published 1994 Journal Pediatr. Nephrol. Section Abstract Doc Link 7947041 Disease Relevance 0.17 Pain Relevance 0.54
Subcutaneous injections of recombinant human erythropoietin (rHuEPO) produce considerable pain which can result in noncompliance.
erythropoietin Binding (injections) of associated with pain
8) Confidence 0.37 Published 1994 Journal Pediatr. Nephrol. Section Abstract Doc Link 7947041 Disease Relevance 0.17 Pain Relevance 0.54
We conclude that the combination of rHuEPO plus lidocaine is as effective as rHuEPO alone in increasing the hematocrit of rats with chronic renal failure.
rHuEPO Binding (combination) of associated with chronic renal failure and lidocaine
9) Confidence 0.37 Published 1994 Journal Pediatr. Nephrol. Section Abstract Doc Link 7947041 Disease Relevance 0.24 Pain Relevance 0.75
Recombinant human EPO (rhEPO) at a dose of 5,000 U/kg (n?
EPO Binding (Recombinant) of
10) Confidence 0.36 Published 2010 Journal PLoS ONE Section Abstract Doc Link PMC2884017 Disease Relevance 0.66 Pain Relevance 0.09
The EPO-specific receptor has been recognized in different cells, such as endothelial cells, epicardium, placenta, pancreatic islets, renal cells and defined areas of the brain [22].
EPO Binding (recognized) of in pancreatic islets
11) Confidence 0.36 Published 2010 Journal World J Surg Oncol Section Body Doc Link PMC2917416 Disease Relevance 0.23 Pain Relevance 0.12
Palliative nutritional intervention in addition to cyclooxygenase and erythropoietin treatment for patients with malignant disease: Effects on survival, metabolism, and function.
erythropoietin Binding (intervention) of associated with malignant neoplastic disease, disease and palliative
12) Confidence 0.36 Published 2004 Journal Cancer Section Title Doc Link 15112279 Disease Relevance 0.38 Pain Relevance 0.19
-binding site of the EPO gene promoter (Fig. 2A), G-CSF at a concentration of 0.1 µg/mL was sufficient to induce DNA binding complex formation.
EPO gene Binding (binding) of
13) Confidence 0.32 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2852409 Disease Relevance 0.14 Pain Relevance 0
In addition, results from blood vessel density quantification by CD31 immunoreactivity (Fig. 6C) show better neovascularization in the penumbral areas of ischemic rats treated with EPO + G-CSF compared to the other three groups (each group n?
EPO Binding (treated) of in blood vessel
14) Confidence 0.32 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2852409 Disease Relevance 0.37 Pain Relevance 0.23
Recombinant EPO and G-CSF have been used clinically for over 20 years [31].
EPO Binding (Recombinant) of
15) Confidence 0.32 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2852409 Disease Relevance 0.34 Pain Relevance 0.12
Increased oligodendrocyte progenitor cells in the I-R brain treated with r-Hu-EPO
r-Hu-EPO Binding (treated) of in brain
16) Confidence 0.32 Published 2010 Journal Anatomy & Cell Biology Section Body Doc Link PMC2998786 Disease Relevance 0.54 Pain Relevance 0.05
Increased endothelial cell proliferation in the I-R brain treated with r-Hu-EPO
r-Hu-EPO Binding (treated) of in brain
17) Confidence 0.32 Published 2010 Journal Anatomy & Cell Biology Section Body Doc Link PMC2998786 Disease Relevance 0.12 Pain Relevance 0.18
Recombinant human EPO (rhEPO) at a dose of 5,000 U/kg (n?
rhEPO Binding (Recombinant) of
18) Confidence 0.32 Published 2010 Journal PLoS ONE Section Abstract Doc Link PMC2884017 Disease Relevance 0.66 Pain Relevance 0.09
Treatment with rhEPO did not increase ipsilateral CNPase immunoreactivity (28.6±1.8%, n?
rhEPO Binding (Treatment) of
19) Confidence 0.32 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2884017 Disease Relevance 0.38 Pain Relevance 0.04
Our results confirmed and extended previous observations that genes associated with hypoxia (specifically VEGF, Flk-1, and EPO) are indeed elevated following hypoxia in the retina.
EPO Binding (associated) of in retina associated with hypoxia
20) Confidence 0.31 Published 2009 Journal Molecular Vision Section Body Doc Link PMC2635851 Disease Relevance 1.26 Pain Relevance 0.03

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox